What Apyx Medical Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 7 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 76,000 |
| Disposed | 0 | 15,557 |
| Net activity | +0 | +60,443 |
Common stock only — 1 reported trade in the last 12 months is in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Waldman Lawrence | Director | Jun 30 | Withheld — tax / exercise cost · F | −5,024 | $4.49 | −$22.6K | 12,314 |
| Waldman Lawrence | Director | Jun 30 | Exercise / conversion · M | +12,000 | $1.88 | +$22.6K | 17,338 |
| Roman Shawn David | Chief Operating Officer | Jun 15 | Withheld — tax / exercise cost · F | −10,533 | $4.60 | −$48.5K | 16,467 |
| Roman Shawn David | Chief Operating Officer | Jun 15 | Exercise / conversion · M | +15,000 | $3.23 | +$48.5K | 15,000 |
| Vizirgianakis Stavros G. | Director | Jun 11 | Grant / award · A | +450,000 | — | — | 2,196,191 |
| Citronowicz Moshe | Senior Vice President | Mar 15 | Exercise / conversion · M | +37,000 | $1.80 | +$66.6K | 493,504 |
| Roman Shawn David | Chief Operating Officer | Jan 27 | Exercise / conversion · M | +12,000 | $1.80 | +$21.6K | 12,000 |
| Hill Mathew C | Chief Financial Officer | Aug 13 | Open-market buy · P | +6,000 | $1.13 | +$6.78K | 8,500 |
| Hill Mathew C | Chief Financial Officer | Dec 12 | Open-market buy · P | +2,500 | $2.19 | +$5.48K | 2,500 |
| Goodwin Charles D. Ii | Chief Executive Officer | Nov 14 | Open-market buy · P | +50,000 | $1.57 | +$78.5K | 90,000 |
| Waldman Lawrence | Director | Jul 12 | Exercise / conversion · M | +5,338 | $2.97 | +$15.9K | 5,338 |
| Hornsby Todd | Executive Vice President | Jun 26 | Open-market sale · S | −15,000 | $7.56 | −$113K | 0 |
| Hornsby Todd | Executive Vice President | Jun 26 | Exercise / conversion · M | +15,000 | $1.77 | +$26.6K | 15,000 |
| Geraghty Michael | Director | Jun 06 | Exercise / conversion · M | +10,000 | $2.79 | +$27.9K | 27,500 |
| Goodwin Charles D. Ii | Chief Executive Officer | Aug 29 | Open-market buy · P | +9,750 | $5.97 | +$58.2K | 40,000 |
| Goodwin Charles D. Ii | Chief Executive Officer | Aug 29 | Open-market buy · P | +2,000 | $5.93 | +$11.9K | 30,250 |
| Waldman Lawrence | Director | Jul 11 | Exercise / conversion · M | +24,000 | $2.54 | +$61K | 37,563 |
| Citronowicz Moshe | Sr. V.P. of Operations | Jul 11 | Exercise / conversion · M | +30,000 | $2.54 | +$76.2K | 456,504 |
| Geraghty Michael | Director | Jul 06 | Exercise / conversion · M | +4,000 | $2.54 | +$10.2K | 17,500 |
| Makrides Andrew | Director | Jul 05 | Withheld — tax / exercise cost · F | −13,583 | $6.14 | −$83.4K | 624,389 |
Loading...
